2017 Breakthroughs in Neurology Conference | SAT02 - Alzheimer’s Disease: Reboot 2017

Date Saturday 01/14/17

Time 08:00 AM - 11:00 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type

Director(s) Richard J. Caselli, MD, FAAN

Topic(s)

Learning Objectives Participants will understand the diverging cognitive and biomarker trajectories of normal and pathological aging, appreciate the genomic complexity of Alzheimer's disease including major and minor risk variants, realize that the majority of patients have mixed forms of dementia rather than pure single diseases, and that this collective knowledge has enabled the launch of secondary prevention trials aimed at presymptomatic individuals at high risk for Alzheimer's dementia.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Practitioner, Fellow, Academician, Resident, Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Didactic

Event Timeline
08:00 AM - 08:05 AM		Introduction Richard J. Caselli, MD, FAAN
08:05 AM - 08:40 AM		The New Era of Preclinical Alzheimer’s Disease Richard J. Caselli, MD, FAAN
08:40 AM - 09:20 AM		Genomics of Alzheimer’s Disease and the Future of Individualized Medicine Matthew Huentelman
09:20 AM - 09:35 AM		Break
09:35 AM - 10:05 AM		The Effects of Neuropathological Complexity in Alzheimer's Disease Thomas Beach
10:05 AM - 10:45 AM		The New Era in Alzheimer's Prevention Research Eric M. Reiman, MD
10:45 AM - 11:00 AM		Panel Q and A

Faculty Disclosures
Richard J. Caselli, MD, FAAN	The institution of Dr. Caselli has received research support from NIA. The institution of Dr. Caselli has received research support from State of Arizona.
Eric M. Reiman, MD	Dr. Reiman has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Denali, Green Valley, Zinfandel, and Takeda. Dr. Reiman has received stock or an ownership interest from Alkahest, Alzheon, Aural Analytics, Denali, and United Neuroscience.. Dr. Reiman has received intellectual property interests from a discovery or technology relating to health care. Dr. Reiman has received personal compensation in the range of $500-$4,999 for serving as a Member, National Advisory Council on Aging (NACA) with NIA.
Thomas Beach	Thomas Beach has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vivid Genomics. Thomas Beach has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche Diagnostics. The institution of Thomas Beach has received research support from National Institutes of Health. The institution of Thomas Beach has received research support from Michael J Fox Foundation . The institution of Thomas Beach has received research support from State of Arizona.
Matthew Huentelman	No disclosure on file

��ɫ��

��ɫ��